A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS ...

Get the best of the Pacific in your inbox!